Humana (HUM) Set to Post Quarterly Earnings on Friday

Humana (NYSE:HUM) will likely be releasing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $40.87 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Humana Stock Down 0.1%

Humana stock opened at $417.32 on Thursday. Humana has a 12 month low of $163.11 and a 12 month high of $456.50. The stock has a fifty day simple moving average of $402.73 and a two-hundred day simple moving average of $310.76. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $50.11 billion, a price-to-earnings ratio of 24.30, a PEG ratio of 2.57 and a beta of 0.65.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be issued a $0.8850 dividend. This represents a $3.54 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is presently 33.49%.

Analyst Ratings Changes

HUM has been the subject of several research reports. Zacks Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. UBS Group raised their target price on shares of Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Raymond James Financial upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $520.00 target price for the company in a research note on Monday, October 12th. Morgan Stanley raised Humana from an “underweight” rating to an “overweight” rating in a report on Friday, October 9th. Finally, Truist Financial increased their price target on Humana from $415.00 to $475.00 and gave the company a “hold” rating in a report on Monday, October 12th. Twenty-one research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Moderate Buy” and an average target price of $453.30.

Humana Company Profile

Humana Inc is a health and well-being company that provides insurance products and health care services in the United States and Puerto Rico. The company’s primary business is government-sponsored health coverage, particularly Medicare Advantage plans for older adults, along with Medicare prescription drug plans, Medicaid coverage and certain commercial health insurance products.

Humana also operates CenterWell, its health care services platform focused on older adults. CenterWell includes primary care clinics, home health services and pharmacy services, with an emphasis on coordinated care, chronic-condition management and helping members receive care in lower-cost settings.

Founded in 1961 as a nursing-home company, Humana expanded into hospital operations before shifting its focus toward health insurance and related services.